Trial · NCT04004442
Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
NCT04004442, Phase 1, Active not recruiting, University of Oklahoma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma. Trials, record NCT04004442. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04004442
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma
- NCT number
- NCT04004442
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 19 participants, actual
- Lead sponsor
- University of Oklahoma
- Conditions
- Urothelial Carcinoma
- Interventions
- Avelumab, AVB-S6-500
- First posted
- 2019-07-02
- Last updated
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability | up to 2 years | To investigate the safety and tolerability of the study drug combination for Avelumab with AVB-S6-500 |
| Secondary | Progression Free Survival | up to two years | period from the time of patient enrollment until disease progression, death, or date of last contact or to the date of censoring (dropout, end of study or death) |
| Secondary | Clinical Benefit Rate | up to two years | proportion of patients with complete or partial response, or stable disease per RECIST 1.1 on treatment with avelumab and ABV-S6-500 |
| Secondary | Duration of Response | up to two years | defined as the period from the date of confirmed tumor response until disease progression, death, or date of last contact or to the date of censoring (dropout, end of study or death) |
| Secondary | Overall Survival | up to two years | the period from patient enrollment until death, or date of last contact or to the date of censoring (end of study) |
| Secondary | Investigator assessed Objective Response Rate | up to 2 years | To evaluate the antitumor efficacy of avelumab and AVB-S6-500 as measured by the objective response rate assessed by the investigator |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04004442
GET https://conductscience.org/api/trials/v1/NCT04004442/registered